The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
[123I]Metaiodobenzylguanidine and[111In]Octreotide Uptake in Benign and Malignant Pheochromocytomas1
Abstract
Selecting the appropriate approach for resection and follow-up of pheochromocytomas (PCCs) is highly dependent upon reliable localization and exclusion of multifocal, bilateral, or metastatic disease. Metaiodobenzylguanidine (MIBG) scintigraphy was developed for functional localization of catecholamine-secreting tissues. Somatostatin receptor imaging (SRI) has a high sensitivity for localizing head and neck paragangliomas, but studies of intraabdominal PCCs are rare. In this study we review our experience of [(123)I]MIBG and SRI, performed since 1983 and 1989, respectively, in the work-up of primary and recurrent PCCs. Scintigraphic results were correlated with catecholamine secretion, size and site, malignancy, associated tumor syndromes, and morphological features. [(123)I]MIBG scans were performed in a total of 75 patients, in 70 cases before resection of primary PCCs and in 5 cases because of recurrent disease. Ninety-one PCCs were resected. The overall detection rates were 83.3% and 89.8% for PCCs larger than 1.0 cm. Multifocal disease was detected in 4 patients with [(123)I]MIBG. [(123)I]MIBG uptake correlated with greater size of PCC (r = 0.33; P = 0.008) and greater concentration of plasma epinephrine (r = 0.32; P = 0.006). [(123)I]MIBG-negative PCCs (n = 14) had significantly (P = 0.01) smaller diameters than [(123I)]MIBG-positive tumors. Furthermore, [(123)I]MIBG uptake was significantly higher in unilateral (P = 0.02), benign (P = 0.02), sporadic (P = 0.02), intraadrenal (P = 0.02), and capsular invasive (P = 0.03) PCCs than in bilateral, malignant, MEN2A/2B-related, extraadrenal, and noninvasive PCCs, respectively. The detection rate of SRI was only 25% (8 of 32) for primary benign PCCs. In 14 patients metastases occurred, which were effectively visualized with [(123)I]MIBG in 8 of 14 cases. SRI was able to detect metastases in 7 of 8 cases, including 3 [(123)I]MIBG-negative metastatic cases. In addition, [(123)I]MIBG and SRI detected 2 recurrences. In conclusion, [(123)I]MIBG uptake is correlated with the size, epinephrine production, and site of PCCs. Its role in bilateral and MEN2A/2B-related PCCs seems limited. In cases of recurrent elevation of catecholamines, localization of metastases and/or recurrence should be attempted with [(123)I]MIBG scintigraphy. In suspicious metastatic PCCs, SRI might be considered to supplement [(123)I]MIBG scintigraphy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F.-M., Orcutt, M. L., Stackhouse, T., Kuzmin, I., Modi, W., Geil, L., et al. (1993) · Science · doi:10.1126/science.8493574 · Cited by 2,973
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P., & Wells, S. A. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.851 · Cited by 1,303
Scintigraphic Localization of Pheochromocytoma
Sisson, J. C., Frager, M. S., Valk, T. W., Gross, M. D., Swanson, D. P., Wieland, D. M., Tobes, M. C., Beierwaltes, W. H., & Thompson, N. W. (1981) · New England Journal of Medicine · doi:10.1056/nejm198107023050103 · Cited by 544
Extra-Adrenal Pheochromocytoma
Whalen, R. K., Althausen, A. F., & Daniels, G. H. (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)37119-7 · Cited by 452
Yttrium-90 DOTATOC: first clinical results
Otte, A., Herrmann, R., Heppeler, A., Behe, M., Jermann, E., Powell, P., Maecke, H. R., & Muller, J. (1999) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050476 · Cited by 420
Early experience with laparoscopic approach for adrenalectomy.
Gagner, M., Lacroix, A., Prinz, R. A., Bolté, E., Albala, D., Potvin, C., Hamet, P., Kuchel, O., Quérin, S., & Pomp, A. (1993) · PubMed · Cited by 380
Shapiro, B., Copp, J., Sisson, J. C., Eyre, P., Wallis, J. W., & Beierwaltes, W. H. (1985) · PubMed · Cited by 344
Yttrium-90-labelled somatostatin-analogue for cancer treatment
Otte, A., Mueller-Brand, J., Dellas, S., Nitzsche, E., Herrmann, R., & Maecke, H. (1998) · The Lancet · doi:10.1016/s0140-6736(05)78355-0 · Cited by 335
Current Management of Pheochromocytoma
REMINE, W. H., CHONC, G. C., VAN HEERDEN, J. A., SHEPS, S. G., & HARRISON, E. G. (1974) · Annals of Surgery · doi:10.1097/00000658-197405000-00029 · Cited by 299
Cited by
Pheochromocytoma: recommendations for clinical practice from the First International Symposium
Pacak, K., Eisenhofer, G., Ahlman, H., Bornstein, S. R., Gimenez-Roqueplo, A.-P., Grossman, A. B., Kimura, N., Mannelli, M., McNicol, A. M., & Tischler, A. S. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0396 · Cited by 680
The diagnosis and medical management of advanced neuroendocrine tumors.
Kaltsas, G. A., Besser, G. M., & Grossman, A. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0014 · Cited by 674
Chen, H., Sippel, R. S., O'Dorisio, M. S., Vinik, A. I., Lloyd, R. V., & Pacak, K. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181ebb4f0 · Cited by 593
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477
Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
Kwekkeboom, D. J., Kam, B. L., van Essen, M., Teunissen, J. J. M., van Eijck, C. H. J., Valkema, R., de Jong, M., de Herder, W. W., & Krenning, E. P. (2010) · Endocrine-Related Cancer · doi:10.1677/erc-09-0078 · Cited by 466
Self-citationTaïeb, D., Hicks, R. J., Hindié, E., Guillet, B. A., Avram, A., Ghedini, P., Timmers, H. J., Scott, A. T., Elojeimy, S., Rubello, D., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04398-1 · Cited by 403
Timmers, H. J. L. M., Kozupa, A., Chen, C. C., Carrasquillo, J. A., Ling, A., Eisenhofer, G., Adams, K. T., Solis, D., Lenders, J. W. M., & Pacak, K. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6297 · Cited by 340
Pheochromocytoma: An Imaging Chameleon
Blake, M. A., Kalra, M. K., Maher, M. M., Sahani, D. V., Sweeney, A. T., Mueller, P. R., Hahn, P. F., & Boland, G. W. (2004) · RadioGraphics · doi:10.1148/rg.24si045506 · Cited by 339
Current Approaches and Recommended Algorithm for the Diagnostic Localization of Pheochromocytoma
Ilias, I., & Pacak, K. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031091 · Cited by 332
Imaging of Neuroendocrine Tumors
Heller, M. T., & Shah, A. B. (2011) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2011.02.011 · Cited by 329
New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification
Crona, J., Taïeb, D., & Pacak, K. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00062 · Cited by 324
NANETS Consensus Guidelines for the Diagnosis of Neuroendocrine Tumor
Vinik, A. I., Woltering, E. A., Warner, R. R. P., Caplin, M., O'Dorisio, T. M., Wiseman, G. A., Coppola, D., & Go, V. L. W. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181ebaffd · Cited by 287
The optimal imaging of adrenal tumours: a comparison of different methods
Ilias, I., Sahdev, A., Reznek, R. H., Grossman, A. B., & Pacak, K. (2007) · Endocrine-Related Cancer · doi:10.1677/erc-07-0045 · Cited by 266
Pheochromocytoma: presentation, diagnosis and treatment
Reisch, N., Peczkowska, M., Januszewicz, A., & Neumann, H. P. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000251887.01885.54 · Cited by 263
EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma
Taïeb, D., Timmers, H. J., Hindié, E., Guillet, B. A., Neumann, H. P., Walz, M. K., Opocher, G., de Herder, W. W., Boedeker, C. C., de Krijger, R. R., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2215-8 · Cited by 256
Self-citationKwekkeboom, D. J., & Krenning, E. P. (2002) · Seminars in Nuclear Medicine · doi:10.1053/snuc.2002.31022 · Cited by 252
Self-citationManger, W. M., & Gifford, R. W. (2002) · The Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2002.01452.x · Cited by 143
Avram, A. M., Fig, L. M., & Gross, M. D. (2006) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2006.03.004 · Cited by 66
Metadata
- Authors
- van der Harst, E., de Herder, W. W., Bruining, H. A., Bonjer, H. J., de Krijger, R. R., Lamberts, S. W. J., van de Meiracker, A. H., Boomsma, F., Stijnen, T., Krenning, E. P., Bosman, F. T., & Kwekkeboom, D. J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2001-02
- Volume
- 86
- Issue
- 2
- Pages
- 685-693
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2121925788
- Cited by
- 253
- References
- 44
- FWCI
- 12.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.